Adding PRN Melatonin for Middle-of-the-Night Awakenings
I would not recommend adding a PRN 3 mg melatonin dose for middle-of-the-night awakenings, as melatonin functions primarily as a chronobiotic (circadian phase-shifter) rather than a traditional hypnotic, and its efficacy depends critically on timing relative to the body's natural melatonin rhythm—not on-demand dosing.
Why This Approach Is Problematic
Melatonin's Mechanism Doesn't Support PRN Use
Melatonin works by binding to M1 and M2 receptors to regulate circadian timing, not by inducing sleep on demand like traditional hypnotics 1. The hormone's sleep-promoting effects occur when administered 1-2 hours before the body's natural dim light melatonin onset (DLMO), typically 2-4 hours before habitual bedtime 2, 3. Taking melatonin in the middle of the night—when endogenous melatonin levels are already elevated—provides no additional circadian signal and minimal hypnotic benefit 4.
The 2026 shift work disorder guidelines specifically note that melatonin's effects are timing-dependent, not dose-dependent 5. When given at inappropriate times, melatonin may cause residual morning sleepiness, cognitive impairment, and increased accident risk 5.
The Current 7.5 mg Dose Is Already Supraphysiological
Your patient is taking 7.5 mg nightly—well above the physiological dose of 0.3 mg that effectively restores normal nocturnal melatonin levels 6. Research demonstrates that 0.3 mg restores sleep efficiency in older adults with insomnia, while higher doses (3 mg) cause hypothermia and prolonged elevation of melatonin into daylight hours without additional sleep benefit 6. Adding another 3 mg PRN would further compound this supraphysiological dosing without addressing the underlying sleep maintenance problem.
What To Do Instead
1. Reassess the Diagnosis
Middle-of-the-night awakenings with difficulty returning to sleep suggests sleep maintenance insomnia, not a circadian rhythm disorder. The current melatonin regimen may be addressing the wrong problem. Consider whether this represents:
- Primary insomnia requiring CBT-I (first-line treatment per multiple guidelines 5, 7)
- Unrecognized sleep-disordered breathing
- Medication effects or comorbid conditions
2. Optimize Current Melatonin Timing and Dose
- Reduce the dose to 0.3-3 mg taken 1-2 hours before desired bedtime (around 6 PM if bedtime is 8-9 PM) 3, 6
- Ensure immediate-release formulation for circadian effects 1
- The 2023 REM sleep behavior disorder guideline notes that melatonin doses can be titrated up to 15 mg in 3-mg increments, but this is for a different indication and doesn't apply to typical insomnia 1
3. Address Sleep Maintenance Specifically
For middle-of-the-night awakenings, evidence-based options include:
- CBT-I: First-line treatment with high-level evidence for insomnia 5, 8, 7
- Dual orexin receptor antagonists (DORAs): The 2026 shift work guidelines suggest suvorexant or other DORAs for sleep disturbance/insomnia 5. The 2016 ACP guideline shows suvorexant (15-20 mg) improves wake after sleep onset (WASO) by 5 minutes and total sleep time by 16 minutes 7
- Melatonin receptor agonists: Ramelteon is suggested for sleep disturbance per AASM guidelines 5, though evidence for sleep maintenance is limited 7
Avoid:
- Benzodiazepines: The 2026 AASM guideline explicitly recommends against triazolam and other benzodiazepines for shift work disorder sleep disturbance 5
- Additional PRN melatonin: No guideline supports this approach
4. Sleep Hygiene and Behavioral Interventions
The 2023 consensus on sleep disturbance recommends 8:
- Avoid caffeine and alcohol
- Eliminate bedroom noise
- Maintain regular sleep schedule
- Routine exercise (not close to bedtime)
Key Caveats
- Melatonin formulation matters: Over-the-counter preparations vary widely in actual melatonin content, with no FDA oversight in the U.S. 9, 4. Look for USP-verified products 10
- Long-term safety: While generally safe at doses ≤10 mg daily, long-term effects remain understudied 10, 11. Common side effects include drowsiness, headache, and GI upset 12
- Drug interactions: Exercise caution with warfarin and in patients with epilepsy 10
The fundamental issue is that your patient has sleep maintenance insomnia being treated with a circadian phase-shifting agent. The solution is not more melatonin at the wrong time, but rather appropriate treatment for the actual sleep disorder—likely CBT-I as first-line, with consideration of a DORA if pharmacotherapy is needed.